Literature DB >> 17509284

Interstitial cystitis and painful bladder syndrome.

Christopher K Payne1, Geoffrey F Joyce, Matthew Wise, J Quentin Clemens.   

Abstract

PURPOSE: We quantified the burden of interstitial cystitis/painful bladder syndrome on the health care system in the United States.
MATERIALS AND METHODS: The analytical methods used to generate these results were described previously. Interstitial cystitis was defined based on International Classification of Diseases, 9th revision code 595.1 (interstitial cystitis). For painful bladder syndrome we used the definition International Classification of Diseases, 9th revision code 788.41 (urinary frequency) with code 625.8 (other specified symptoms associated with female genital organs) or 625.9 (unspecified symptoms associated with female genital organs).
RESULTS: Between 1992 and 2001 there was a 2-fold increase in the rate of hospital outpatient visits and a 3-fold increase in the rate of physician office visits related to interstitial cystitis. The annualized rate was 102 office visits per 100,000 population. Ambulatory surgery for interstitial cystitis decreased. A diagnosis of interstitial cystitis was associated with a 2-fold increase in direct medical costs. Between 1994 and 2000 annual national expenditures for interstitial cystitis were stable at $37 million but annual costs for painful bladder syndrome increased from $481 million to $750 million.
CONCLUSIONS: Although interstitial cystitis accounts for a small percent of health care visits, its economic burden is substantial. Because of misdiagnosis, the true burden of interstitial cystitis/painful bladder syndrome on the health care system in the United States is probably underestimated in administrative data that rely only on physician coding to identify the disorder. The greatest part of the disease burden is likely not captured in this economic analysis.

Entities:  

Mesh:

Year:  2007        PMID: 17509284     DOI: 10.1016/j.juro.2007.01.124

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  29 in total

Review 1.  Interstitial cystitis/bladder pain syndrome: diagnosis and management.

Authors:  I Offiah; S B McMahon; B A O'Reilly
Journal:  Int Urogynecol J       Date:  2013-02-22       Impact factor: 2.894

2.  Psychosocial co-morbidities in Interstitial Cystitis/Bladder Pain syndrome (IC/BPS): A systematic review.

Authors:  Lindsey C McKernan; Colin G Walsh; William S Reynolds; Leslie J Crofford; Roger R Dmochowski; David A Williams
Journal:  Neurourol Urodyn       Date:  2017-10-09       Impact factor: 2.696

3.  The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study.

Authors:  Anne M Suskind; Sandra H Berry; Brett A Ewing; Marc N Elliott; Marika J Suttorp; J Quentin Clemens
Journal:  J Urol       Date:  2012-11-16       Impact factor: 7.450

4.  Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin.

Authors:  Hitoshi Yokoyama; Katsumi Sasaki; Michael E Franks; William F Goins; James R Goss; William C de Groat; Joseph C Glorioso; Michael B Chancellor; Naoki Yoshimura
Journal:  Hum Gene Ther       Date:  2009-01       Impact factor: 5.695

5.  A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides.

Authors:  Siam Oottamasathien; Wanjian Jia; Lindsi McCoard; Sean Slack; Jianxing Zhang; Aleksander Skardal; Kathleen Job; Thomas P Kennedy; Randal O Dull; Glenn D Prestwich
Journal:  J Urol       Date:  2011-08-19       Impact factor: 7.450

6.  Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes.

Authors:  Mary P FitzGerald; Rodney U Anderson; Jeannette Potts; Christopher K Payne; Kenneth M Peters; J Quentin Clemens; Rhonda Kotarinos; Laura Fraser; Annemarie Cosby; Carole Fortman; Cynthia Neville; Suzanne Badillo; Lisa Odabachian; Andrea Sanfield; Betsy O'Dougherty; Rick Halle-Podell; Liyi Cen; Shannon Chuai; J Richard Landis; Keith Mickelberg; Ted Barrell; John W Kusek; Leroy M Nyberg
Journal:  J Urol       Date:  2009-06-17       Impact factor: 7.450

7.  Role of nicotinic and estrogen signaling during experimental acute and chronic bladder inflammation.

Authors:  Magaly Martinez-Ferrer; Juan M Iturregui; Consolate Uwamariya; Jonathan Starkman; Ali-Reza Sharif-Afshar; Kichiya Suzuki; Wit Visedsindh; Robert J Matusik; Roger R Dmochowski; Neil A Bhowmick
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

8.  Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines.

Authors:  Claus Riedl; Paul Engelhardt; Bernhard Schwarz
Journal:  Clin Drug Investig       Date:  2013-10       Impact factor: 2.859

9.  Life impact of urologic pain syndromes.

Authors:  Lena Hatchett; Mary Pat Fitzgerald; Jeannette Potts; Abigail Winder; Keith Mickelberg; Ted Barrell; John W Kusek
Journal:  J Health Psychol       Date:  2009-09

10.  Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain.

Authors:  W F Goins; J R Goss; M B Chancellor; W C de Groat; J C Glorioso; N Yoshimura
Journal:  Gene Ther       Date:  2009-02-26       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.